Business Wire

AtlasEdge Further Expands Coverage Across Europe with Acquisition of Twelve Data Centres from Colt Data Centre Services (DCS)

2.11.2021 12:00:00 EET | Business Wire | Press release

Share

AtlasEdge, a pan-European edge data centre provider, has today announced the successful acquisition of twelve data centres. The deal is with Colt DCS, a world-class provider of Hyperscale data centres across Europe & APAC.

The successful acquisition from Colt strengthens AtlasEdge’s unique portfolio of distributed data centres that are positioned to support localised or low latency applications. AtlasEdge now operates more than 100 data centres across eleven countries in Europe, supporting more than 700 customers and providing connectivity to more than 50 different on-net carriers.

AtlasEdge provides a pan-European data centre portfolio that allows customers to design and configure their technology and network infrastructure to meet the growing requirements for lower latency, higher performance and localised solutions. With demand gravitating towards the edge of networks, AtlasEdge’s distributed and highly connected footprint provides a unique solution that is aligned with the next wave of growth in digital infrastructure.

This acquisition further expands AtlasEdge’s coverage and accelerates time to market in several new geographies, as well as establishing a collaboration between AtlasEdge and Colt Data Centre Services, with Colt Technology Services becoming an anchor tenant across multiple facilities. This network-neutral colocation strategy enables AtlasEdge’s customers to optimise their network routes, minimise their bandwidth costs and take advantage of the wide community of cloud, content, technology and enterprise companies present in the facilities.

The portfolio includes data centers in key tier one and tier two markets across Europe, including Amsterdam, Barcelona, Berlin, Brussels, Copenhagen, Hamburg, London, Madrid, Milan, Paris and Zurich.

We are delighted to welcome these sites into our expanding portfolio,” commented Josh Joshi, Executive Chairman, AtlasEdge. “We are tapping into an exciting and emerging market where real time data traffic is growing and compute is gravitating to the edge of the network. As this demand builds, AtlasEdge is uniquely positioned to deliver seamless, localised and ultra-low latency digital infrastructure to our customers — from cloud providers to streaming services and enterprises. Our approach is open, carrier neutral and collaborative, and we look forward to working alongside Colt.”

Niclas Sanfridsson, CEO, Colt DCS, added, “Demand for data storage and cloud capabilities has never been higher, and so is the need for businesses to scale and find capacity. By restructuring and focusing on our hyperscale facilities, we can meet our customers’ needs on demand with true scalability and efficiency, while meeting their sustainability targets. We are committed to ensuring a sustainable business model for the future and this latest deal will improve the returns on investment across our portfolio, which can then be reinvested into the business.”

ABOUT AtlasEdge

AtlasEdge is a European edge data centre business with a mission to create Europe’s leading edge platform, delivering seamless, localised and ultra-low latency digital infrastructure to customers. Formed through a joint investment by Liberty Global, one of the world’s leading converged video, broadband and communications companies and DigitalBridge, a leading global investment firm dedicated to digital infrastructure, AtlasEdge already has an expanding portfolio of more than 100 data centres across the continent, providing proximity to the core network that is critical for the technology of tomorrow.

For more information, please visit www.atlasedge.com

ABOUT Colt DCS

Colt Data Centre Services provide true service and operational excellence in the sustainable design, build, delivery and operational management of hyperscale data centres across Europe and the APAC. We provide data centre solutions to hyperscale and large enterprise customers across 14 state of the art carrier neutral data centres spanning 8 cities. Our Hyperscale and colocation solutions allow our customers the freedom to plan effectively for the growth of their business, knowing that their data centre strategy is ready for the demands of tomorrow. We have over 25 years of experience in the industry, delivering on our vision of being the most trusted and customer centric data center operator in the market. We put environmental awareness at the heart of everything we do because we know it’s the right thing to do for our planet. That’s why we’re taking the ownership to reduce our environmental impact globally and make sustainability a key strategic driver. As part of our sustainability journey, alongside our sister company we are committed to achieving global net zero emissions for our own operations by 2030. https://www.coltdatacentres.net/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

AtlasEdge Corporate Communications:
Duncan White | duncan.white@atlasedge.com | +44 7970 974832

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye